AbbVie Inc.

ABBV

US00287Y1091

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2024-04-22 pm EDT			5-day change	1st Jan Change
167.9 ^USD	+0.89%		+3.85%	+8.34%

Apr. 22	Pfizer: new Emblaveo antibiotic approved in the EU	CF
Apr. 19	Sector Update: Health Care Stocks Advance Late Afternoon	MT

Abbvie Declares Quarterly Dividend, Payable on August 15, 2022

June 23, 2022 at 03:43 pm EDT

The board of directors of AbbVie Inc. declared a quarterly cash dividend of $1.41 per share. The cash dividend is payable August 15, 2022, to stockholders of record at the close of business on July 15, 2022.

Latest news about AbbVie Inc.

Pfizer: new Emblaveo antibiotic approved in the EU	Apr. 22	CF
Sector Update: Health Care Stocks Advance Late Afternoon	Apr. 19	MT
Sector Update: Health Care Stocks Rise Friday Afternoon	Apr. 19	MT
Sector Update: Health Care	Apr. 19	MT
Alvotech Shares Rise After Signing Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US	Apr. 19	MT
Deutsche Bank Raises AbbVie's Price Target to $175 Form $170	Apr. 19	MT
Alvotech Signs Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US	Apr. 19	MT
Global markets live: DocMorris, Microsoft, Oracle, Micron, Netflix...	Apr. 18
AbbVie Says Potential Treatment for Giant Cell Arteritis Met Endpoints in Phase 3 Study	Apr. 18	MT
AbbVie Study on Treatment for Giant Cell Arteritis Meets Primary Endpoint	Apr. 18	DJ
AbbVie Announces Positive Top-Line Results from SELECT-GCA Study of Upadacitinib Showed Positive Results in Patients with Giant Cell Arteritis	Apr. 18	CI
OSE: licensing agreement with AbbVie enters into force	Apr. 17	CF
OSE Immunotherapeutics Finalizes Drug License, Collaboration Deal With AbbVie	Apr. 17	MT
Medincell: share price rises following agreement with AbbVie	Apr. 17	CF
Medincell, AbbVie to Co-Develop Injectable Therapeutics	Apr. 16	DJ
AbbVie Says Phase 3 Interim Data Support Long-Term Efficacy, Safety of Migraine Drug	Apr. 12	MT
AbbVie Inc. Announces Late-Breaking Data At Aan Supporting Long-Term Safety and Efficacy of Atogepant (Qulipta®) for Prevention of Migraine	Apr. 12	CI
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease	Apr. 08	RE
Boehringer to lay off salespeople as Humira biosimilar sales lag	Apr. 05	RE
Boehringer to lay off salespeople as Humira biosimilar sales lag	Apr. 04	RE
AbbVie Flags Hit to Q1 Adjusted Earnings from R&D Expenses, Revises 2024 Outlook	Apr. 04	MT
US takes next step in Medicare drug price negotiations with pharma companies	Apr. 02	RE
Roivant's anti-inflammatory drug succeeds in mid-stage study	Apr. 02	RE
Barclays Raises AbbVie Price Target to $195 From $185, Maintains Overweight Rating	Mar. 27	MT
Deals of the day-Mergers and acquisitions	Mar. 25	RE

Chart AbbVie Inc.

Duration

Period

More charts

Company Profile

AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).

Sector

Pharmaceuticals

Calendar

2024-04-25 - Q1 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for AbbVie Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

167.9 USD

Average target price

184.1 USD

Spread / Average Target

+9.68%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ABBVIE INC.	+8.34%	297B
ELI LILLY AND COMPANY	+25.46%	659B
NOVO NORDISK A/S	+26.72%	557B
JOHNSON & JOHNSON	-4.86%	359B
MERCK & CO., INC.	+16.44%	322B
ASTRAZENECA PLC	+6.55%	215B
NOVARTIS AG	+7.31%	210B
ROCHE HOLDING AG	-6.18%	200B
PFIZER, INC.	-8.79%	149B
AMGEN INC.	-5.59%	146B

Other Pharmaceuticals

AbbVie Inc.

Equities

ABBV

US00287Y1091

Pharmaceuticals

Abbvie Declares Quarterly Dividend, Payable on August 15, 2022

EPS Revisions